World's Best Scientists 2026 revealed!
Ian F. Tannock

Ian F. Tannock

D-Index & Metrics

Medicine

D-Index
131
Citations
81127
World Ranking
2359
National Ranking
91

Overview

Ian F. Tannock is affiliated with the University of Toronto in Canada. Their primary research focus lies within the field of Medicine, with significant contributions in several subfields including Pulmonary and Respiratory Medicine, Economics and Econometrics, Oncology, Cancer Research, and Statistics and Probability.

The scientist's main research topics encompass Cancer Genomics and Diagnostics, Health Systems, Economic Evaluations, Quality of Life, Statistical Methods in Clinical Trials, Economic and Financial Impacts of Cancer, Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations, and Prostate Cancer Diagnosis and Treatment.

Their recent published papers include:

  • The Lancet Commission on prostate cancer: planning for the surge in cases (2024, The Lancet)
  • Priorities for cancer research in low- and middle-income countries: a global perspective (2022, Nature Medicine)
  • Informative censoring - a neglected cause of bias in oncology trials (2020, Nature Reviews Clinical Oncology)
  • Common Sense Oncology: outcomes that matter (2023, The Lancet Oncology)
  • Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap (2020, Journal of Clinical Oncology)

Frequent co-authors collaborating with Ian F. Tannock include:

  • Christopher M. Booth
  • Daniel A. Goldstein
  • Bishal Gyawali
  • Elizabeth A. Eisenhauer
  • Dario Trapani

The scholar has published extensively in prominent venues, notably:

  • The Lancet Oncology (12 publications)
  • Journal of Clinical Oncology (10 publications)
  • Annals of Oncology (10 publications)
  • JAMA Oncology (4 publications)
  • Nature Reviews Clinical Oncology (3 publications)

Best Publications

  • Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    Ian F. Tannock;Ronald de Wit;William R. Berry;Jozsef Horti

  • Drug penetration in solid tumours

    Andrew I. Minchinton;Ian F. Tannock

  • Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

    Arnoud J. Templeton;Mairéad G. McNamara;Boštjan Šeruga;Francisco E. Vera-Badillo

  • Drug Resistance and the Solid Tumor Microenvironment

    Olivier Trédan;Carlos M Galmarini;Krupa Patel;Ian F Tannock

  • Acid pH in Tumors and Its Potential for Therapeutic Exploitation

    Ian F. Tannock;Daniela Rotin

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

    I. F. Tannock;D. Osoba;M. R. Stockler;D. S. Ernst

  • Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon

  • Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

    Dominik R. Berthold;Gregory R. Pond;Freidele Soban;Ronald de Wit

  • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau

  • A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    P J Loehrer;L H Einhorn;P J Elson;E D Crawford

  • The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour.

    I F Tannock

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Cytokines and their relationship to the symptoms and outcome of cancer.

    Bostjan Seruga;Haibo Zhang;Lori J. Bernstein;Ian F. Tannock

  • Repopulation of cancer cells during therapy: an important cause of treatment failure

    John J. Kim;Ian F. Tannock

  • Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

    Christine B. Brezden;Kelly-Anne Phillips;Mohamed Abdolell;Terry Bunston

  • Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    S B Saxman;K J Propert;L H Einhorn;E D Crawford

  • Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

    M. K B Parmar;M. Adams;M. Balestrino;K. Bertelsen

  • Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

    Arnoud J. Templeton;Olga Ace;Mairéad G. McNamara;Mustafa Al-Mubarak

  • Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.

    Ian F Tannock;Carol M Lee;Jonathon K Tunggal;David S M Cowan

Frequent Co-Authors

Gregory R. Pond
Gregory R. Pond McMaster University
George Tomlinson
George Tomlinson University of Toronto
Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Padraig Warde
Padraig Warde Princess Margaret Cancer Centre
Neil Fleshner
Neil Fleshner Princess Margaret Cancer Centre
Andrew J. Armstrong
Andrew J. Armstrong Duke University
Malcolm J. Moore
Malcolm J. Moore Princess Margaret Cancer Centre
Susan Halabi
Susan Halabi Duke University
Pamela J. Goodwin
Pamela J. Goodwin University of Toronto
Gordon Winocur
Gordon Winocur University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean following the traditional medical school path. Numerous accredited online programs offer flexible, accessible routes into healthcare fields. For registered nurses looking to advance their credentials quickly, adn to np programs online allow professionals to bridge from an Associate Degree in Nursing to a Nurse Practitioner role, often while continuing to work.

Those interested in health and wellness can pursue an online nutrition degree to build expertise in food science, dietetics, and preventive healthcare—key areas as public interest in nutrition surges.

For aspiring leaders, top online mha programs that are cahme accredited provide rigorous training in healthcare administration, preparing graduates to manage hospitals and healthcare systems with cutting-edge skills.

Additionally, online rn to bsn programs no clinicals support nurses in upgrading their qualifications without the challenge of on-site clinical requirements, streamlining career growth for busy professionals.

Each of these online degrees opens doors to rewarding roles in healthcare, tailored for students seeking flexible study options and diverse career pathways.

Best Scientists Citing Ian F. Tannock

Trending Scientists

Recently Published Articles